How can B cell-based biomarkers be used for disease diagnosis and prognosis?

Jan 17, 2025 ... Cutaneous B-cell lymphoma is a cancer that starts in the white blood cells and attacks the skin. It often causes a lump or group of lumps on the skin. May 28, 2019 ... Because we used to think that T cells were the major problem, DMTs often target those cells. But now we see that drugs targeting B cells are ... The finding gives oncologists a new target for developing immunotherapies: double negative memory B cells, so-called because they are negative for two markers. Sep 7, 2022 ... Preeclampsia (PE), new onset hypertension (HTN) during pregnancy, is associated with placental ischemia and chronic inflammation that ... Sep 7, 2017 ... The US Food and Drug Administration granted regular approval to tisagenlecleucel (KYMRIAH, Novartis Pharmaceuticals Corp.) for the treatment of patients up to ... A biologic subset of diffuse large B-cell lymphomas with a unique molecular signature or expression profile. CD20 is a B cell-specific membrane protein and represents an attractive target for therapeutic antibodies. Despite widespread usage of anti-CD20 antibodies ... Apr 21, 2015 ... To date, two models of Breg cell development can be suggested. The first is that Breg cells, similar to thymus-derived Treg cells, are a ... Apr 12, 2024 ... Current WHO B cell lymphoma classification features the following major updates (Int J Lab Hematol 2017;39:14): Newly defined high grade B cell lymphomas. Aug 19, 2024 ... This trial represents the largest randomized study of radiotherapy in PMBCL to date. Despite encountering challenges due to unexpectedly good ...